What is Akari Therapeutics, Plc's current stock price?

Akari Therapeutics, Plc (AKTX) currently trades at USD 7.52. Track real-time price changes and historical performance on AllInvestView.

What sector is Akari Therapeutics, Plc in?

Akari Therapeutics, Plc operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Akari Therapeutics, Plc AKTX · Stock Open Akari Therapeutics, Plc in new tab

7.52 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Akari Therapeutics, Plc (AKTX)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Akari Therapeutics, Plc Analysis (AKTX)

United Kingdom Health Care Official Website Stock

Is Akari Therapeutics, Plc a good investment? Akari Therapeutics, Plc (AKTX) is currently trading at 7.52 USD.

Earnings Schedule: Akari Therapeutics, Plc is expected to release its next earnings report on Aug. 18, 2026.

Investor FAQ

Does Akari Therapeutics, Plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Akari Therapeutics, Plc?

Akari Therapeutics, Plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 18, 2026.

Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Exchange Ticker

NMS (United States) AKTX

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
Sept. 17, 2015	0.100000
Aug. 17, 2023	0.050000
March 31, 2026	0.030000

Akari Therapeutics, Plc AKTX · Stock Open Akari Therapeutics, Plc in new tab

Key Metrics

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Akari Therapeutics, Plc Analysis (AKTX)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Akari Therapeutics, Plc AKTX · Stock Open Akari Therapeutics, Plc in new tab

Key Metrics

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Akari Therapeutics, Plc Analysis (AKTX)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications